News release

From:

Study shows how GLP-1 obesity drugs are associated with reduced systemic inflammation beyond their anti-obesity effects

A meta-analysis of ten randomised controlled trials and more than 23,000 participants presented at this year’s International Congress on Obesity (ICO 2026) hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15-17) shows that the GLP-1 class of obesity drugs are associated with a marked reduction in systemic inflammation beyond their anti-obesity effects, potentially showing how they are able to reduce cardiovascular risk factors. The study is by Dr Mario Cesar Torres Chavez, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, and colleagues.

Chronic low-grade inflammation is a key biological mechanism linking obesity to adverse cardiometabolic outcomes. High-sensitivity C-reactive protein (hsCRP) is a validated marker of systemic inflammation and an independent predictor of cardiovascular risk.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to promote weight loss and improve cardiometabolic risk factors in adults without diabetes; however, their impact on systemic inflammatory burden, and whether this effect differs across clinically relevant conditions such as heart failure with preserved ejection fraction (HFpEF), remains insufficiently studied. To find out more, the authors did a meta-analysis of randomised controlled trials to calculate the effect of GLP-1RA therapy on hsCRP and to assess potential effect modification by HFpEF status.

A systematic search of PubMed, Scopus, and Web of Science was performed to identify randomised controlled trials evaluating GLP-1RA therapy in adults without diabetes (thus only being treated for weight loss) that reported changes in hsCRP.

Ten randomised controlled trials comprising 23,652 participants were included. GLP-1RA therapy was associated with a significant approximately 45% reduction in hsCRP compared with placebo. The greatest reduction, of around 48%, occurred in individuals with obesity and weight-related cardiometabolic comorbidities. Patients with HFpEF saw a reduction of approximately 38%, and those with established cardiovascular disease showed a similar reduction of around 38%. No significant difference in hsCRP reduction was detected between semaglutide and tirzepatide.

The authors say: “In adults without diabetes, GLP-1 receptor agonist therapy is associated with a robust reduction in systemic inflammation as reflected by this protein used to measure inflammation. The magnitude of this anti-inflammatory effect depends on baseline clinical characteristics, being greatest in individuals with obesity-related conditions and smaller, though still significant, in those with heart failure with preserved ejection fraction and established cardiovascular disease. These findings support inflammation modulation as a contributing mechanism to the cardiovascular benefits of GLP-1RAs, independent of improvements in blood sugar control, and highlight the need for mechanistic trials to establish the specific contribution of inflammation reduction to clinical outcomes.”